

Precision AQ Research at ISPOR EU 2026

November 8 – 11 | Vienna, Austria | Booth #918

NOVEMBER 9

POSTER TITLE	PRECISION AQ PRESENTERS	SESSION #	SESSION
A Structured Framework for Evidence Prioritization to Support SLR and ITC in Joint Clinical Assessments: Application in ALK+ NSCLC	Milica Jevdjovic, PhD, Manasi Thosar, MSc, Jonathon Briggs, PhD, Chloi Theriou, BSc, Andrew Frederickson, MS, Walter Bouwmeester, PhD	HTA26	10:30-13:30 Poster Session 1
The Biosecure Effect: EU Market Access Implications for China-Originated PD-(L)1 Inhibitors	Richard Macaulay, BA, PhD, Alistair Blair, BSc, MSc, Anwen Tay, BSc	HTA13	10:30-13:30 Poster Session 1
Value Delayed Is Value Denied: Cost-Effectiveness Challenges for Presymptomatic Gene Therapies	Richard Macaulay, BA, PhD, Lewis Hall, MEng, EngD	HTA6	10:30-13:30 Poster Session 1
Are MEAs Delivering on Their Promise? Evidence From EU5 Payer Perspectives	Richard Macaulay, BA, PhD, Rebecca Andrews, MChem, Rachael McRobb, BSc, MSc	HPR49	10:30-13:30 Poster Session 1
EU5 Payer Readiness for Anti-Ageing Therapeutics: Awareness, Concern, and Anticipated Reimbursement Hurdles	Richard Macaulay, BA, PhD, Rebecca Andrews, MChem, Rachael McRobb, BSc, MSc	HTA1	10:30-13:30 Poster Session 1
Asymmetric Convergence: MFN and JCA Reforms Reshape Global Access Strategy but All Eyes are on the US, Not Europe	Emma Hawe, BSc, MSc, Andrea Berardi, MSc	HTA124	16:00-19:00 Poster Session 2
Closing the Gap: Quantifying MFN Pricing Exposure and Strategic Responses in Medicare	Richard Macaulay, BA, PhD, Asra Shah, MSc	HPR101	16:00-19:00 Poster Session 2
From Policy Innovation to Practical Access: Early Implementation Challenges of China's Commercial Insurance Innovative Drug List	Chloe Wang, MSc	HPR83	16:00-19:00 Poster Session 2
Health State Utilities Before and After Revascularization for Atherosclerotic Cardiovascular Disease: A Systematic Literature Review and Meta-Regression Analysis	Andrew Frederickson, MS	EE162	16:00-19:00 Poster Session 2
Navigating MFN Exposure: Non-Public Reimbursement Pathways for Ultra-rare Therapies Outside Europe	Akshit Nayar, MSc, Jasmine Sultana, MBioChem, Anwen Tay, BSc, Richard Macaulay, BA, PhD	HPR73	16:00-19:00 Poster Session 2

POSTER TITLE	PRECISION AQ PRESENTERS	SESSION #	SESSION
Understanding the Social Value Manufacturer Revenue and Reinvestment – A Case Study Using Palbociclib in HR+/HER2- Advanced Breast Cancer	Jacki Chou, MPP, MPL, Marlon Graf, MPP, PhD, Thomas Flottemesch, MS, PhD	EE382	10:30-13:30 Poster Session 3
Quantifying the Societal Value of Resmetirom for Metabolic Dysfunction Associated Steatohepatitis Using a Societal Value Modeling Approach	Thomas Flottemesch, PhD, Marlon Graf, MPP, PhD, Jacki Chou, MPP, MPL, Iris Brewer, MS, Amal Jamaledine, MSc, James Baumgardner, PhD	EE333	10:30-13:30 Poster Session 3
Methods for Modelling Immature Overall Survival (OS) in Breast Cancer (BC) in National Institute for Health and Care Excellence (NICE) Technology Appraisals (TAs)	Alicia N. Pepper, PhD, Melody Zhao, MSc, Eesha Kodi, MPH, Eleanor Paul, MSc	HTA179	10:30-13:30 Poster Session 3
Investigating the Correlation Between Progression-free Survival (PFS) and Overall Survival (OS) in First-Line (1L) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)	Ali Mojebi, MD, Dylan Maciel, MSc, Oluwaseun Egunsola, PhD	SA50	10:30-13:30 Poster Session 3
Most Favoured Nation, Least Favoured Markets? EU5 Payer Perspectives on US Pricing Reforms	Richard Macaulay, BA, PhD, Rebecca Andrews, MChem, Rachael McRobb, BSc, MSc	HPR162	10:30-13:30 Poster Session 3
Treat Now, Prove Later? EU5 Payer Perspectives on Pre-Symptomatic Gene Therapy for Huntington's Disease	Richard Macaulay, BA, PhD, Rebecca Andrews, MChem, Rachael McRobb, BSc, MSc	HTA172	10:30-13:30 Poster Session 3
JCA Reality Check: Diverging Payer Readiness for Medicines vs. Medical Devices in the EU	Richard Macaulay, BA, PhD, Dimitrios Tzaras, MSc	HTA236	10:30-13:30 Poster Session 3
From Price Compression to Lifecycle Value Management: Implications of China's 2026 Drug Pricing Reform	Chloe Wang, MSc	P38	13:45-14:45 Podium Session
Modern Synthesis Methods for Estimating Subgroup-Specific Treatment Effects	Jeroen Jansen, PhD Harlan Campbell, PhD		13:45-14:45 Workshop
Beyond Cost-Effectiveness: Estimating the Social Value of Palbociclib Over its Lifecycle	Jacki Chou, MPP, MPL, Marlon Graf, MPP, PhD, Thomas Flottemesch, MS, PhD	EE528	16:00-19:00 Poster Session 4
MFN Shockwaves Beyond the US: Evidence of Accelerated German Launches, Selective Non-Entry	Richard Macaulay, BA, PhD, Costanza Alciati, MSc	HPR215	16:00-19:00 Poster Session 4
Have NICE's Increased Cost-Effectiveness Thresholds Improved Technology Appraisal Outcomes?	Richard Macaulay, BA, PhD, Rebecca Andrews, MChem	HTA319	16:00-19:00 Poster Session 4
Incremental Tightening of Japan's Drug Pricing System: Implications of the FY2026 Reform	Chloe Wang, MSc, Rebecca Andrews, MChem	EE606	16:00-19:00 Poster Session 4

Distinguishing Verification from Judgment in Human-in-the-Loop Evidence Synthesis	Andrew Frederickson, MS	MSR212	16:00-19:00 Poster Session 4
Joint Versus Independent Modeling of Progression-Free and Overall Survival in NICE Oncology Appraisals: A Review and Simulation Study of the Impact on Decision Uncertainty	Emma Hawe, BSc, MSc, Andrea Berardi, MSc	MSR197	16:00-19:00 Poster Session 4
Beyond the Headlines: Surfacing Under-Recognised HEOR & Market-Access Trends through a Structured 12-Month Environmental Scan	Emma Hawe, BSc, MSc, Andrea Berardi, MSc	HPR194	16:00-19:00 Poster Session 4
Statistical Lessons from Early EU Joint Clinical Assessments and Implications for Rare-Disease HTA Across EU-25: The Role of Early Automation in Identifying Evidence Gaps	Emma Hawe, BSc, MSc, Lydia Vinals, MSc, PhD	P43	16:45-17:45 Podium Session

NOVEMBER 11

POSTER TITLE	PRECISION AQ PRESENTERS	SESSION #	SESSION
A Summary of Guidance and Methods for Identification of Prognostic Factors in a Systematic Review for a JCA Dossier Evidence Synthesis Workflow	Jonathon Briggs, PhD, Walter Bouwmeester, PhD, Milica Jevdjevic, PhD, Andrew Frederickson, MS	SA106	9:00-11:30 Poster Session 5
Capacity Building or Concentration? Early Patterns of Assessor and Co-Assessor Participation in European Union Joint Clinical Assessments	Lydia Vinals, MSc, PhD, Kevin Towle, MSc, Jenny Chen, MSc, Emma Hawe, BSc, MSc	HTA395	9:00-11:30 Poster Session 5
New Avenues or Dead Ends? Evaluating Private Health Insurance and Out-of-Pocket Pharmaceutical Access Across Five European Markets	Richard Macaulay, BA, PhD, Sam Coates, BA, Ethan James Prince, MBiochem.	HPR269	9:00-11:30 Poster Session 5
Impact of US Most-Favoured Nation (MFN) Pricing Policy on pCPA Negotiation Activity in Canada	Richard Macaulay, BA, PhD, Rebecca Andrews, MChem	HTA403	9:00-11:30 Poster Session 5
From PICO to Practice: Advancing Evidence Synthesis	Jeroen Jansen, PhD		10:00-11:00 Podium Session



Visit us at Booth #918
November 8 – 11 | Vienna, Austria